Your browser doesn't support javascript.
loading
A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome
Vadim Demichev; Pinkus Tober-Lau; Tatiana Nazarenko; Charlotte Thibeault; Harry Whitwell; Oliver Lemke; Annika Röhl; Anja Freiwald; Lukasz Szyrwiel; Daniela Ludwig; Clara Correia-Melo; Elisa Theresa Helbig; Paula Stubbemann; Nana-Maria Grüning; Oleg Blyuss; Spyros Vernardis; Matthew White; Christoph B. Messner; Michael Joannidis; Thomas Sonnweber; Sebastian J. Klein; Alex Pizzini; Yvonne Wohlfarter; Sabina Sahanic; Richard Hilbe; Benedikt Schaefer; Sonja Wagner; Mirja Mittermaier; Felix Machleidt; Carmen Garcia; Christoph Ruwwe-Glösenkamp; Tilman Lingscheid; Laure Bosquillon de Jarcy; Miriam S. Stegemann; Moritz Pfeiffer; Linda Jürgens; Sophy Denker; Daniel Zickler; Philipp Enghard; Aleksej Zelezniak; Archie Campbell; Caroline Hayward; David J. Porteous; Riccardo Marioni; Alexander Uhrig; Holger Müller-Redetzky; Heinz Zoller; Judith Löffler-Ragg; Markus A. Keller; Ivan Tancevski; John F. Timms; Alexey Zaikin; Stefan Hippenstiel; Michael Ramharter; Martin Witzenrath; Norbert Suttorp; Kathryn Lilley; Michael Mülleder; Leif Erik Sander; - PA-COVID-19 Study group; Markus Ralser; Florian Kurth.
Affiliation
  • Vadim Demichev; The Francis Crick Institute
  • Pinkus Tober-Lau; Charité - Universitätsmedizin Berlin
  • Tatiana Nazarenko; University College London
  • Charlotte Thibeault; Charite Universitaetsmedizin Berlin
  • Harry Whitwell; Imperial College London
  • Oliver Lemke; Charité - Universitätsmedizin Berlin
  • Annika Röhl; Charité - Universitätsmedizin Berlin
  • Anja Freiwald; Charité - Universitätsmedizin Berlin
  • Lukasz Szyrwiel; The Francis Crick Institute
  • Daniela Ludwig; Charité - Universitätsmedizin Berlin
  • Clara Correia-Melo; The Francis Crick Institute
  • Elisa Theresa Helbig; Charité - Universitätsmedizin Berlin
  • Paula Stubbemann; Charité - Universitätsmedizin Berlin
  • Nana-Maria Grüning; Charité - Universitätsmedizin Berlin
  • Oleg Blyuss; Lobachevsky University
  • Spyros Vernardis; The Francis Crick Institute
  • Matthew White; The Francis Crick Institute
  • Christoph B. Messner; Charité - Universitätsmedizin Berlin
  • Michael Joannidis; Medical University of Innsbruck
  • Thomas Sonnweber; Medical University of Innsbruck
  • Sebastian J. Klein; Medical University of Innsbruck
  • Alex Pizzini; Medical University of Innsbruck
  • Yvonne Wohlfarter; Medical University of Innsbruck
  • Sabina Sahanic; Medical University of Innsbruck
  • Richard Hilbe; Medical University of Innsbruck
  • Benedikt Schaefer; Medical University of Innsbruck
  • Sonja Wagner; Medical University of Innsbruck
  • Mirja Mittermaier; Charité - Universitätsmedizin Berlin
  • Felix Machleidt; Charité - Universitätsmedizin Berlin
  • Carmen Garcia; Charité - Universitätsmedizin Berlin
  • Christoph Ruwwe-Glösenkamp; Charité - Universitätsmedizin Berlin
  • Tilman Lingscheid; Charité - Universitätsmedizin Berlin
  • Laure Bosquillon de Jarcy; Charité - Universitätsmedizin Berlin
  • Miriam S. Stegemann; Charité - Universitätsmedizin Berlin
  • Moritz Pfeiffer; Charité - Universitätsmedizin Berlin
  • Linda Jürgens; Charité - Universitätsmedizin Berlin
  • Sophy Denker; Charité - Universitätsmedizin Berlin
  • Daniel Zickler; Charité - Universitätsmedizin Berlin
  • Philipp Enghard; Charité - Universitätsmedizin Berlin
  • Aleksej Zelezniak; The Francis Crick Institute
  • Archie Campbell; The University of Edinburgh
  • Caroline Hayward; The University of Edinburgh
  • David J. Porteous; The University of Edinburgh
  • Riccardo Marioni; University of Edinburgh
  • Alexander Uhrig; Charité - Universitätsmedizin Berlin
  • Holger Müller-Redetzky; Charité - Universitätsmedizin Berlin
  • Heinz Zoller; Medical University of Innsbruck
  • Judith Löffler-Ragg; Medical University of Innsbruck
  • Markus A. Keller; Medical University of Innsbruck
  • Ivan Tancevski; Medical University of Innsbruck
  • John F. Timms; University College London
  • Alexey Zaikin; University College London
  • Stefan Hippenstiel; Charité - Universitätsmedizin Berlin
  • Michael Ramharter; Bernhard Nocht Institute for Tropical Medicine
  • Martin Witzenrath; Charité - Universitätsmedizin Berlin
  • Norbert Suttorp; Charité - Universitätsmedizin Berlin
  • Kathryn Lilley; The University of Cambridge
  • Michael Mülleder; Charité - Universitätsmedizin Berlin
  • Leif Erik Sander; Charité - Universitätsmedizin Berlin
  • - PA-COVID-19 Study group;
  • Markus Ralser; Charite University Medicine
  • Florian Kurth; Charité - Universitätsmedizin Berlin
Preprint in English | medRxiv | ID: ppmedrxiv-20228015
ABSTRACT
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There is an urgent need for predictive markers that can guide clinical decision-making, inform about the effect of experimental therapies, and point to novel therapeutic targets. Here, we characterize the time-dependent progression of COVID-19 through different stages of the disease, by measuring 86 accredited diagnostic parameters and plasma proteomes at 687 sampling points, in a cohort of 139 patients during hospitalization. We report that the time-resolved patient molecular phenotypes reflect an initial spike in the systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution and immunomodulation. Further, we show that the early host response is predictive for the disease trajectory and gives rise to proteomic and diagnostic marker signatures that classify the need for supplemental oxygen therapy and mechanical ventilation, and that predict the time to recovery of mildly ill patients. In severely ill patients, the molecular phenotype of the early host response predicts survival, in two independent cohorts and weeks before outcome. We also identify age-specific molecular response to COVID-19, which involves increased inflammation and lipoprotein dysregulation in older patients. Our study provides a deep and time resolved molecular characterization of COVID-19 disease progression, and reports biomarkers for risk-adapted treatment strategies and molecular disease monitoring. Our study demonstrates accurate prognosis of COVID-19 outcome from proteomic signatures recorded weeks earlier.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
...